Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA. James ND, et al. BJU Int. 2010 Oct;106(7):966-73. doi: 10.1111/j.1464-410X.2010.09638.x. BJU Int. 2010. PMID: 20840318 Clinical Trial.
Is gene therapy the answer for prostate cancer?
Patel P, Ashdown D, James N. Patel P, et al. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S14-9. doi: 10.1038/sj.pcan.4500743. Prostate Cancer Prostatic Dis. 2004. PMID: 15365577
Future development of penile cancer services in the UK.
Singh R, James ND, Watkin NA. Singh R, et al. Among authors: james nd. BJU Int. 2004 Nov;94(7):967-9. doi: 10.1111/j.1464-410X.2004.05084.x. BJU Int. 2004. PMID: 15541109 No abstract available.
Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. James ND, et al. Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29. Eur Urol. 2009. PMID: 19042080 Clinical Trial.
A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].
Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, Doherty A, Leung H, Young LS, James ND. Patel P, et al. Among authors: james nd. Mol Ther. 2009 Jul;17(7):1292-9. doi: 10.1038/mt.2009.80. Epub 2009 Apr 14. Mol Ther. 2009. PMID: 19367257 Free PMC article. Clinical Trial.
Biomarkers in bladder cancer.
Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK. Bryan RT, et al. Among authors: james nd. BJU Int. 2010 Mar;105(5):608-13. doi: 10.1111/j.1464-410X.2009.08880.x. Epub 2009 Sep 29. BJU Int. 2010. PMID: 19793380 Free article. Review.
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, Dwyer J, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann GN, Bertelli G, Birtle AJ, O'Sullivan JM, Protheroe A, Sheehan D, Srihari N, Parmar MK; STAMPEDE investigators. James ND, et al. Lancet Oncol. 2012 May;13(5):549-58. doi: 10.1016/S1470-2045(12)70088-8. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452894 Free PMC article. Clinical Trial.
229 results